{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:52:56Z","timestamp":1783662776515,"version":"3.55.0"},"reference-count":84,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03CA181893"],"award-info":[{"award-number":["R03CA181893"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA174926 to J.L.F."],"award-info":[{"award-number":["R01CA174926 to J.L.F."]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32CA009213 to J.N.C."],"award-info":[{"award-number":["T32CA009213 to J.N.C."]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA023074"],"award-info":[{"award-number":["P30CA023074"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012639","name":"METAvivor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012639","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Phoenix Chapter of ARCS Foundation"},{"name":"Louise Foucar Marshall Foundation Dissertation Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Breast cancer bone metastases (BMET) are incurable, primarily osteolytic, and occur most commonly in estrogen receptor-\u03b1 positive (ER+) breast cancer. ER+ human breast cancer BMET modeling in mice has demonstrated an estrogen (E2)-dependent increase in tumor-associated osteolysis and bone-resorbing osteoclasts, independent of estrogenic effects on tumor proliferation or bone turnover, suggesting a possible mechanistic link between tumoral ER\u03b1-driven osteolysis and ER+ bone progression. To explore this question, inducible secretion of the osteolytic factor, parathyroid hormone\u2013related protein (PTHrP), was utilized as an in vitro screening bioassay to query the osteolytic potential of estrogen receptor- and signaling pathway\u2013specific ligands in BMET-forming ER+ human breast cancer cells expressing ER\u03b1, ER\u00df, and G protein\u2013coupled ER. After identifying genomic ER\u03b1 signaling, also responsibility for estrogen's proliferative effects, as necessary and sufficient for osteolytic PTHrP secretion, in vivo effects of a genomic-only ER agonist, estetrol (E4), on osteolytic ER+ BMET progression were examined. Surprisingly, while pharmacologic effects of E4 on estrogen-dependent tissues, including bone, were evident, E4 did not support osteolytic BMET progression (vs robust E2 effects), suggesting an important role for nongenomic ER signaling in ER+ metastatic progression at this site. Because bone effects of E4 did not completely recapitulate those of E2, the relative importance of nongenomic ER signaling in tumor vs bone cannot be ascertained here. Nonetheless, these intriguing findings suggest that targeted manipulation of estrogen signaling to mitigate ER+ metastatic progression in bone may require a nuanced approach, considering genomic and nongenomic effects of ER signaling on both sides of the tumor\/bone interface.<\/jats:p>","DOI":"10.1210\/endocr\/bqae038","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T03:37:30Z","timestamp":1715139450000},"source":"Crossref","is-referenced-by-count":4,"title":["Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice"],"prefix":"10.1210","volume":"165","author":[{"given":"Julia N","family":"Cheng","sequence":"first","affiliation":[{"name":"Cancer Biology Graduate Interdisciplinary Program, University of Arizona , Tucson, AZ 85724 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B","family":"Frye","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona , Tucson, AZ 86724 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A","family":"Whitman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona , Tucson, AZ 86724 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Ehsani","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona , Tucson, AZ 86724 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-0816","authenticated-orcid":false,"given":"Simak","family":"Ali","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer, Imperial College London , London W12 0NN , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9826-5407","authenticated-orcid":false,"given":"Janet L","family":"Funk","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Arizona , Tucson, AZ 86724 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,5,8]]},"reference":[{"issue":"1","key":"2024052704514030200_bqae038-B1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"2024052704514030200_bqae038-B2","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/bjc.2014.5","article-title":"Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics","volume":"110","author":"Colzani","year":"2014","journal-title":"Br J Cancer"},{"issue":"10","key":"2024052704514030200_bqae038-B3","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1158\/1055-9965.EPI-12-0474","article-title":"Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades","volume":"21","author":"Haque","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"2024052704514030200_bqae038-B4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1309\/AJCPYO5FSV3UPEXS","article-title":"Breast cancer subtypes predispose the site of distant metastases","volume":"143","author":"Soni","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"10087","key":"2024052704514030200_bqae038-B5","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/S0140-6736(16)32419-9","article-title":"Advances in the treatment of advanced oestrogen-receptor-positive breast cancer","volume":"389","author":"Turner","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"2024052704514030200_bqae038-B6","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1080\/07357900802574496","article-title":"The prognostic impact of bone marrow micrometastases in women with breast cancer","volume":"27","author":"Braun","year":"2009","journal-title":"Cancer Invest"},{"issue":"8","key":"2024052704514030200_bqae038-B7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMoa050434","article-title":"A pooled analysis of bone marrow micrometastasis in breast cancer","volume":"353","author":"Braun","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"2024052704514030200_bqae038-B8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12079-011-0117-3","article-title":"Breast cancer at bone metastatic sites: recent discoveries and treatment targets","volume":"5","author":"Hussein","year":"2011","journal-title":"J Cell Commun Signal"},{"issue":"1","key":"2024052704514030200_bqae038-B9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/1471-2407-12-403","article-title":"Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study","volume":"12","author":"Falck","year":"2012","journal-title":"BMC Cancer"},{"key":"2024052704514030200_bqae038-B10","doi-asserted-by":"crossref","first-page":"100367","DOI":"10.1016\/j.jbo.2021.100367","article-title":"Natural history of stage II\/III breast cancer, bone metastasis and the impact of adjuvant zoledronate on distribution of recurrences","volume":"28","author":"D'Oronzo","year":"2021","journal-title":"J Bone Oncol"},{"issue":"8","key":"2024052704514030200_bqae038-B11","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3109\/0284186X.2012.754990","article-title":"Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer","volume":"52","author":"Aurilio","year":"2013","journal-title":"Acta Oncol"},{"issue":"3","key":"2024052704514030200_bqae038-B12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10549-010-1264-6","article-title":"Acquisition of metastatic tissue from patients with bone metastases from breast cancer","volume":"129","author":"Hilton","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2024052704514030200_bqae038-B13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/bjc.1989.264","article-title":"Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence","volume":"60","author":"Kamby","year":"1989","journal-title":"Br J Cancer"},{"issue":"1","key":"2024052704514030200_bqae038-B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2011-1057","article-title":"Derailed estrogen signaling and breast cancer: an authentic couple","volume":"34","author":"Manavathi","year":"2013","journal-title":"Endocr Rev"},{"issue":"5","key":"2024052704514030200_bqae038-B15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2174\/092986713804999303","article-title":"Treatment of estrogen receptor-positive breast cancer","volume":"20","author":"Lumachi","year":"2013","journal-title":"Curr Med Chem"},{"issue":"20","key":"2024052704514030200_bqae038-B16","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"issue":"19","key":"2024052704514030200_bqae038-B17","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"2024052704514030200_bqae038-B18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41523-018-0075-5","article-title":"Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer","volume":"4","author":"Kuang","year":"2018","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"2024052704514030200_bqae038-B19","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jnci\/djab202","article-title":"The incidence of breast cancer recurrence 10-32 years after primary diagnosis","volume":"114","author":"Pedersen","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2024052704514030200_bqae038-B20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1177\/1758834015608993","article-title":"Optimal management of hormone receptor positive metastatic breast cancer in 2016","volume":"7","author":"Reinert","year":"2015","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"2024052704514030200_bqae038-B21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mdx483","article-title":"Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer","volume":"29","author":"Fribbens","year":"2018","journal-title":"Ann Oncol"},{"key":"2024052704514030200_bqae038-B22","first-page":"004","article-title":"Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management","volume":"15","author":"D\u2019Oronzo","year":"2019","journal-title":"J Bone Oncol"},{"issue":"1","key":"2024052704514030200_bqae038-B23","first-page":"321","article-title":"Bone metastases: an overview","volume":"11","author":"Macedo","year":"2017","journal-title":"Oncol Rev"},{"issue":"17","key":"2024052704514030200_bqae038-B24","article-title":"Osteolytic effects of tumoral estrogen signaling in estrogen receptor-positive breast cancer bone metastasis progression in mice","volume":"7","author":"Cheng","year":"2021","journal-title":"J Cancer Metastasis Treat."},{"issue":"2","key":"2024052704514030200_bqae038-B25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10585-019-10012-3","article-title":"Skeletal impact of 17\u03b2-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation","volume":"37","author":"Cheng","year":"2020","journal-title":"Clin Exp Metastasis"},{"issue":"11","key":"2024052704514030200_bqae038-B26","first-page":"3059","article-title":"Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites","volume":"51","author":"Powell","year":"1991","journal-title":"Cancer Res"},{"issue":"23","key":"2024052704514030200_bqae038-B27","first-page":"7710","article-title":"Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer","volume":"50","author":"Southby","year":"1990","journal-title":"Cancer Res"},{"issue":"9","key":"2024052704514030200_bqae038-B28","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.3390\/ijms22094463","article-title":"A role for TGF\u03b2 signaling in preclinical osteolytic estrogen receptor-positive breast cancer bone metastases progression","volume":"22","author":"Cheng","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"27","key":"2024052704514030200_bqae038-B29","doi-asserted-by":"crossref","first-page":"24571","DOI":"10.1074\/jbc.M202561200","article-title":"Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways","volume":"277","author":"Kakonen","year":"2002","journal-title":"J Biol Chem"},{"issue":"49","key":"2024052704514030200_bqae038-B30","doi-asserted-by":"crossref","first-page":"46661","DOI":"10.1074\/jbc.M105816200","article-title":"Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad\/Ets synergism","volume":"276","author":"Lindemann","year":"2001","journal-title":"J Biol Chem"},{"issue":"10C","key":"2024052704514030200_bqae038-B31","first-page":"15","article-title":"Role of TGF- \u03b2 in breast cancer bone metastases","volume":"4","author":"Chiechi","year":"2014","journal-title":"Adv Biosci Biotechnol"},{"issue":"3","key":"2024052704514030200_bqae038-B32","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1530\/ERC-12-0389","article-title":"A bi-faceted role of estrogen receptor \u03b2 in breast cancer","volume":"20","author":"Leygue","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2024052704514030200_bqae038-B33","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1158\/0008-5472.CAN-09-3068","article-title":"The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells","volume":"70","author":"Ariazi","year":"2010","journal-title":"Cancer Res"},{"key":"2024052704514030200_bqae038-B34","first-page":"1045","article-title":"Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications","volume":"97","author":"Arnal","year":"2017","journal-title":"Am Physiol Soc"},{"issue":"17","key":"2024052704514030200_bqae038-B35","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1093\/emboj\/19.17.4688","article-title":"Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1","volume":"19","author":"Flouriot","year":"2000","journal-title":"EMBO J"},{"issue":"6","key":"2024052704514030200_bqae038-B36","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1124\/mol.108.046854","article-title":"17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30","volume":"74","author":"Kleuser","year":"2008","journal-title":"Mol Pharmacol"},{"key":"2024052704514030200_bqae038-B37","first-page":"135","volume-title":"Estrogen Receptor Signaling Mechanisms","author":"Fuentes","year":"2019"},{"issue":"4","key":"2024052704514030200_bqae038-B38","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1210\/endrev\/bnab041","article-title":"Membrane-initiated estrogen, androgen, and progesterone receptor signaling in health and disease","volume":"43","author":"Mauvais-Jarvis","year":"2022","journal-title":"Endocr Rev"},{"issue":"10","key":"2024052704514030200_bqae038-B39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1043-2760(02)00634-3","article-title":"Estrogen action and cytoplasmic signaling pathways. Part II: the role of growth factors and phosphorylation in estrogen signaling","volume":"13","author":"Driggers","year":"2002","journal-title":"Trends Endocrinol Metab"},{"issue":"10","key":"2024052704514030200_bqae038-B40","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.15252\/emmm.201404112","article-title":"The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor modulation, uncoupling nuclear and membrane activation","volume":"6","author":"Abot","year":"2014","journal-title":"EMBO Mol Med"},{"issue":"19","key":"2024052704514030200_bqae038-B41","doi-asserted-by":"crossref","first-page":"17621","DOI":"10.18632\/oncotarget.4184","article-title":"Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms","volume":"6","author":"G\u00e9rard","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"2024052704514030200_bqae038-B42","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.3390\/cancers13102486","article-title":"Estetrol combined to progestogen for menopause or contraception indication is neutral on breast cancer","volume":"13","author":"Gallez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2024052704514030200_bqae038-B43","doi-asserted-by":"crossref","first-page":"29473","DOI":"10.1038\/srep29473","article-title":"The role of membrane ER\u03b1 signaling in bone and other major estrogen responsive tissues","volume":"6","author":"Gustafsson","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"2024052704514030200_bqae038-B44","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1210\/en.2015-1994","article-title":"Role of ER\u03b1MISS in the effect of estradiol on cancellous and cortical femoral bone in growing female mice","volume":"157","author":"Vinel","year":"2016","journal-title":"Endocrinology"},{"issue":"1-2","key":"2024052704514030200_bqae038-B45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jsbmb.2008.12.013","article-title":"Clinical applications for estetrol","volume":"114","author":"Visser","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"7","key":"2024052704514030200_bqae038-B46","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1172\/JCI118947","article-title":"Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis","volume":"98","author":"Guise","year":"1996","journal-title":"J Clin Invest"},{"issue":"3","key":"2024052704514030200_bqae038-B47","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1021\/np300663v","article-title":"Curcuminoids block TGF-\u03b2 signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis","volume":"76","author":"Wright","year":"2013","journal-title":"J Nat Prod"},{"issue":"11","key":"2024052704514030200_bqae038-B48","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-\u03b2 mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat Med"},{"key":"2024052704514030200_bqae038-B49","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1038\/s41388-022-02483-8","article-title":"Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer","volume":"41","author":"Harrod","year":"2022","journal-title":"Oncogene"},{"key":"2024052704514030200_bqae038-B50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jnutbio.2018.09.021","article-title":"Curcumin, but not curcumin-glucuronide, inhibits Smad signaling in TGF\u03b2-dependent bone metastatic breast cancer cells and is enriched in bone compared to other tissues","volume":"63","author":"Kunihiro","year":"2019","journal-title":"J Nutr Biochem"},{"key":"2024052704514030200_bqae038-B51","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.mce.2016.11.016","article-title":"Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity","volume":"440","author":"Nelson","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"2024052704514030200_bqae038-B52","doi-asserted-by":"crossref","first-page":"108842","DOI":"10.1016\/j.jnutbio.2021.108842","article-title":"Curcumin inhibition of TGF\u03b2 signaling in bone metastatic cancer cells and the possible role of oxidative metabolites","volume":"99","author":"Kunihiro","year":"2022","journal-title":"J Nutr Biochem"},{"issue":"1","key":"2024052704514030200_bqae038-B53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/JOE-14-0549","article-title":"Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation","volume":"224","author":"G\u00e9rard","year":"2015","journal-title":"J Endocrinol"},{"issue":"1","key":"2024052704514030200_bqae038-B54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.reprotox.2011.05.005","article-title":"4-Vinylcyclohexene diepoxide (VCD) inhibits mammary epithelial differentiation and induces fibroadenoma formation in female Sprague Dawley rats","volume":"32","author":"Wright","year":"2011","journal-title":"Reprod Toxicol"},{"issue":"1","key":"2024052704514030200_bqae038-B55","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024052704514030200_bqae038-B56","doi-asserted-by":"crossref","first-page":"6460","DOI":"10.1038\/s41598-017-06614-0","article-title":"Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells","volume":"7","author":"Streicher","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"2024052704514030200_bqae038-B57","doi-asserted-by":"crossref","first-page":"14299","DOI":"10.1038\/s41598-018-32653-2","article-title":"Enrichment and detection of bone disseminated tumor cells in models of low tumor burden","volume":"8","author":"Sowder","year":"2018","journal-title":"Sci Rep"},{"key":"2024052704514030200_bqae038-B58","article-title":"Supplementary materials for: interrogating estrogen signaling pathways in human ER-positive breast cancer cells forming bone metastases in mice","author":"Cheng","year":"2024","journal-title":"University of Arizona Research Data Repository"},{"issue":"429","key":"2024052704514030200_bqae038-B59","doi-asserted-by":"crossref","first-page":"ra53","DOI":"10.1126\/scisignal.aad8170","article-title":"Design of pathway preferential estrogens that provide beneficial metabolic and vascular effects without stimulating reproductive tissues","volume":"9","author":"Madak-Erdogan","year":"2016","journal-title":"Sci Signal"},{"issue":"27","key":"2024052704514030200_bqae038-B60","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1038\/onc.2015.414","article-title":"MTORC1 directly phosphorylates and activates ER\u03b1 upon estrogen stimulation","volume":"35","author":"Alayev","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"2024052704514030200_bqae038-B61","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/cr.2008.328","article-title":"Non-Smad pathways in TGF-beta signaling","volume":"19","author":"Zhang","year":"2009","journal-title":"Cell Res"},{"issue":"Pt 21","key":"2024052704514030200_bqae038-B62","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1113\/jphysiol.2009.177097","article-title":"Membrane oestrogen receptor alpha signalling to cell functions","volume":"587","author":"Levin","year":"2009","journal-title":"J Physiol"},{"issue":"1","key":"2024052704514030200_bqae038-B63","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/mend.16.1.0757","article-title":"ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions","volume":"16","author":"Razandi","year":"2002","journal-title":"Mol Endocrinol"},{"issue":"16","key":"2024052704514030200_bqae038-B64","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1128\/MCB.22.16.5835-5845.2002","article-title":"Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation","volume":"22","author":"Lee","year":"2002","journal-title":"Mol Cell Biol"},{"issue":"11","key":"2024052704514030200_bqae038-B65","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4161\/cbt.20992","article-title":"Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation","volume":"13","author":"Antoon","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"2024052704514030200_bqae038-B66","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1091\/mbc.e08-09-0898","article-title":"Specific activation of mitogen-activated protein kinase by transforming growth factor-beta receptors in lipid rafts is required for epithelial cell plasticity","volume":"20","author":"Zuo","year":"2009","journal-title":"Mol Biol Cell"},{"issue":"6","key":"2024052704514030200_bqae038-B67","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0002-9440(10)65498-3","article-title":"Estrogen receptor-positive proliferating cells in the normal and precancerous breast","volume":"155","author":"Shoker","year":"1999","journal-title":"Am J Pathol"},{"issue":"5","key":"2024052704514030200_bqae038-B68","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"issue":"46","key":"2024052704514030200_bqae038-B69","doi-asserted-by":"crossref","first-page":"42908","DOI":"10.1074\/jbc.M105316200","article-title":"Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3","volume":"276","author":"Matsuda","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"2024052704514030200_bqae038-B70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1530\/ERC-17-0563","article-title":"Molecular basis of distinct oestrogen responses in endometrial and breast cancer","volume":"26","author":"Baxter","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2024052704514030200_bqae038-B71","doi-asserted-by":"crossref","first-page":"e1002770","DOI":"10.1371\/journal.pgen.1002770","article-title":"Genome-wide location analysis reveals distinct transcriptional circuitry by paralogous regulators Foxa1 and Foxa2","volume":"8","author":"Bochkis","year":"2012","journal-title":"PLoS Genet"},{"issue":"1","key":"2024052704514030200_bqae038-B72","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cell.2005.05.008","article-title":"Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1","volume":"122","author":"Carroll","year":"2005","journal-title":"Cell"},{"issue":"21","key":"2024052704514030200_bqae038-B73","doi-asserted-by":"crossref","first-page":"16135","DOI":"10.1074\/jbc.M109.088096","article-title":"Foxa1 functions as a pioneer transcription factor at transposable elements to activate Afp during differentiation of embryonic stem cells","volume":"285","author":"Taube","year":"2010","journal-title":"J Biol Chem"},{"issue":"4","key":"2024052704514030200_bqae038-B74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1242\/dmm.028274","article-title":"In vivo models in breast cancer research: progress, challenges and future directions","volume":"10","author":"Holen","year":"2017","journal-title":"Dis Model Mech"},{"issue":"6","key":"2024052704514030200_bqae038-B75","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/cells8060621","article-title":"Patient-Derived Xenograft models of breast cancer and their application","volume":"8","author":"Murayama","year":"2019","journal-title":"Cells"},{"key":"2024052704514030200_bqae038-B76","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/bonekey.2016.31","article-title":"Murine models of breast cancer bone metastasis","volume":"5","author":"Wright","year":"2016","journal-title":"Bonekey Rep"},{"issue":"Suppl 7","key":"2024052704514030200_bqae038-B77","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1186\/s12864-016-2911-z","article-title":"Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer","volume":"17","author":"Jiang","year":"2016","journal-title":"BMC Genomics"},{"issue":"10","key":"2024052704514030200_bqae038-B78","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1210\/endo.140.10.7037","article-title":"Breast cancer cells interact with osteoblasts to support osteoclast formation","volume":"140","author":"Thomas","year":"1999","journal-title":"Endocrinology"},{"issue":"11","key":"2024052704514030200_bqae038-B79","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1096\/fj.13-234617","article-title":"Mechanisms enforcing the estrogen receptor \u03b2 selectivity of botanical estrogens","volume":"27","author":"Jiang","year":"2013","journal-title":"FASEB J"},{"issue":"10","key":"2024052704514030200_bqae038-B80","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1210\/endo.141.10.7698","article-title":"Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members","volume":"141","author":"Kraichely","year":"2000","journal-title":"Endocrinology"},{"issue":"26","key":"2024052704514030200_bqae038-B81","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1021\/jm000170m","article-title":"Pyrazole ligands: structure\u2014affinity\/activity relationships and estrogen receptor-\u03b1-selective agonists","volume":"43","author":"Stauffer","year":"2000","journal-title":"J Med Chem"},{"issue":"1","key":"2024052704514030200_bqae038-B82","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1021\/jm201436k","article-title":"Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor \u03b2-selective ligands","volume":"55","author":"Carroll","year":"2012","journal-title":"J Med Chem"},{"issue":"5","key":"2024052704514030200_bqae038-B83","doi-asserted-by":"crossref","first-page":"057005","DOI":"10.1289\/EHP2387","article-title":"Hydroxylated polybrominated biphenyl ethers exert estrogenic effects via non-genomic G protein\u2013coupled estrogen receptor mediated pathways","volume":"126","author":"Cao","year":"2018","journal-title":"Environ Health Perspect"},{"issue":"4","key":"2024052704514030200_bqae038-B84","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nchembio775","article-title":"Virtual and biomolecular screening converge on a selective agonist for GPR30","volume":"2","author":"Bologa","year":"2006","journal-title":"Nat Chem Biol"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/6\/bqae038\/57874585\/bqae038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/165\/6\/bqae038\/57874585\/bqae038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T04:58:12Z","timestamp":1716785892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqae038\/7666784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,4,29]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqae038","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,4,29]]},"article-number":"bqae038"}}